Company intelligence / Profile preview

Densmore

Ownership: Private
Development stage: Other

Overview

Densmore specializes in commercialized ophthalmic solutions such as KERADROP for inflammatory eye conditions, distributes dietary supplements like MEMOPTIC for vision/memory/cognition support, and acts as a regional distributor for third-party health products such as Zestra. No evidence of ongoing clinical trials or prescription drug development.

Therapeutic areas: OphthalmologyNeurologyWomen's Health
Modalities: Small molecule (for eye drops and supplements)Dietary supplement (for products like MEMOPTIC)Device (potentially for ophthalmic solutions)
Industry: Therapeutic Medical Devices

Partnerships

Innovus Pharmaceuticals/Innovus Pharma – distribution partnership for Zestra in France/Belgium/Monaco

Beyond the preview

Go deeper on Densmore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Densmore.